Fibroblast growth factor(FGF-1)lacks amino-terminal signal peptide, so it can't release through the classical endoplasmic reticulum(ER)-Golgi pathway.
酸性成纤维生长因子-1（FGF-1）由于氨基端缺乏信号肽序列，不能通过经典的内质网-高尔基体途径释放。
ObjectiveTo evaluate the correlation between the promoter polymorphism of Fibroblast Growth Factor 1 (FGF-1) and late-onset Alzheimer's disease (LOAD).
目的探讨成纤维细胞生长因子1（FGF-1）基因启动子多态性是否与晚发型阿尔茨海默病（LOAD）相关。
FGF-1 is involved in many pathological processes, so the measures to disturb or inhibit FGF-1 release pathway provide a new strategy for the diseases directed by FGF-1.
FGF - 1与许多病理过程有关，因而一些干预FGF - 1释放途径的措施为治疗FGF - 1介导的疾病提供了新的思路。
Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the carboxy terminus of human FGF receptor 1 protein.
该单克隆抗体是通过用重组蛋白免疫动物而制备的，该重组蛋白是人FGF受体1蛋白的羧基末端。
Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the carboxy terminus of human FGF receptor 1 protein.
该单克隆抗体是通过用重组蛋白免疫动物而制备的，该重组蛋白是针对人FGF受体1蛋白的羧基末端。
FGF-2, a potent agonist of Egr-1, plays an important role vascular repair after injury.
作为早期生长反应基因-1的增效剂，纤维生长因子-2 在损伤后的血管修复中起着重要的作用。
FGF-2, a potent agonist of Egr-1, plays an important role vascular repair after injury.
作为早期生长反应基因-1的增效剂，纤维生长因子-2 在损伤后的血管修复中起着重要的作用。
应用推荐